Group items tagged

"Optimizing Value: Awarded Grants List of grants awarded in 2015 as part of the Robert Wood Johnson  Foundation's solicitation "Optimizing Value in Health Care: Consumer-focused Trends from the Field," which supports studies that address consumer perceptions of value in the new and emerging health care landscape."

"The Leichtag Foundation honors the legacy of Lee and Toni Leichtag through igniting and inspiring vibrant Jewish life, advancing self-sufficiency and stimulating social entrepreneurship in coastal North San Diego County and Jerusalem. Since its inception in 1991, the Leichtag Foundation has granted over $119 million to 391 different organizations. Of this amount, over $104 million has been granted since becoming independent in late 2007. About 23% has stayed in Encinitas. [Updated August 2017]"

The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) is an integrated database and analytics hub that is designed to be used in building novel tools to accelerate drug development across rare diseases. It is being developed by the Critical Path Institute (C-Path) and NORD through a collaborative grant from the FDA [Critical Path Public-Private Partnerships Grant Number U18 FD005320 from the US Food and Drug Administration].

We welcome applications from organizations that hold a valid charitable status with either the IRS (in the United States), a local tax service/charity commission, or a local TechSoup Global partner. Also, your organization must not be any of following: A legislative or political activity organization A church, association of churches, or other religious organization A school, college, or a related organization* A government office An organization that attempts to influence public opinion A hospital, organization involved with health insurance or group health plans, or a related organization A private grant-making, independent, or operating foundation

DeAunne Denmark, MD, PhD: "To date, the FDA has granted EUA for only these 4 companies: Cellex, Ortho Clinical Diagnostics, Chembio Diagnostic Systems and the Mount Sinai Laboratory. Really looking forward to the validation and head-to-head comparison data promised here from the FDA, Chan Zuckerberg (supposedly this week?), and others. That should be telling... "

Explanation from DeAunne Denmark, MD, PhD : And just to clarify for all, since all of the testing jargon and landscape can be *extremely* confusing, especially now: The FDA has currently relaxed regulations for COVID diagnostics under "Emergency Use" (EUA). This authorizes, not approves, test kits, machines and devices to run those kits, and all other aspects involved in diagnostic testing. Authorize vs approve are very different animals under FDA. And you will see this repeatedly emphasized on the FDA site. But most often neglected, skipped over, mistaken in the wider press. Many articles and press releases use "approve" which is technically wrong - they mean authorize, or "grant use", or "use will not be objected to by FDA." If you have the stamina, I highly recommended reading as much of this as you can: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2 "Validation" is yet an additional aspect that is probably the grayest zone of all, since it is left to each company/testing entity how exactly this is done. Validation can range from excellent to pretty cruddy science and still meet FDA "standards". These will be the devilish details we need to sort out re: collaborating with partners. And will unfortunately likely be a big mess for many outpatient Drs trying to figure out which test to order.

"The San Diego Botanic Garden in Encinitas is expanding its plant curation and preservation efforts into medicine with a $384,000 grant from The Conrad Prebys Foundation, the garden announced March 8."

"RTNF envisions a world where all people enjoy equal opportunities to achieve health, purpose, and happiness. We make sizable, enabling grants to those adventurous organizations we believe have the ability to propel the world closer to achieving that vision, concentrating on the following two populations:"

UCSD received a 5 million dollar grant from the NOORDA foundation. The research product will be slow in coming. NOORDA wants to work with N=1 patients

A message from Sharon: Please support Project Apollo Team as they "Ride Out Lyme to raise funds for Lyme research & to support patients! The 2nd annual event, we raised $10,000 last year. The money is split between BAL to support research and ROL for grants to patients over the age of 26 with financial need. We hope to earmark money raised by ROL La Jolla for San Diego patients in 2021, but this year the money is open to anyone in the US. The mission of Bay Area Lyme "to make Lyme disease easy to diagnose and simple to cure" and we plan to submit a "Measured Lyme" research proposal from Project Apollo in the coming year. Sharon, Mike and Meg will ride as part of the Project Apollo team. Others are welcome! We would love your support as a rider or with donations! To donate to Team Project Apollo visit https://rideoutlyme.salsalabs.org/lajolla2020/t/projectapollo/index.html Let's empower people to realize optimal health!

"Prospective consent and governance principles for participant-led research Nine themes emerged from discussions and interviews relating to informed consent in and governance of PLR. As this PLR was driven by people with different backgrounds asking personal questions, we found that ethical reflection needed to be ongoing and tailored to the individual. For this reason, prospective governance principles were drafted rather than codified rules. Many of the themes were expressed over the course of our PLR as an ongoing informed consent. The process, fostered via frequent communication, helped to reinforce trust among participants and organisers.43 44 Transparency: All relevant information about the project should be actively shared among participants and participant-organisers, including the source of research funding, equipment selection, data management protocols, risks and benefits and conflicts of interest. Access to Expertise: Participant-led research (PLR) requires access to experts (eg, in experimental design, data analysis, research ethics) so that participants can rigorously carry out single-subject experiments.45 Data Access & Control: The participant has the right and ability to manage their own data, and has the final say in what they collect about themselves. Right to Withdraw: Participants have a right to reduce or withdraw their participation at any time. Relevance: PLR addresses questions of relevance to the participants. Beneficence: The participant actively reflects on the balance of benefits and risks of participation and freely choose whether to participate. Responsibility: PLR requires that the participant actively consider the potential benefits and harms of the project to both themselves and others. The responsibility to stay informed is an ongoing process, not a one-time decision. Flexibility: Ethical reflection in PLR should be tailored to individual needs and to the specific context, rather than be handled with 'one size fits all�

Recommended by Tyler Orion: "People who think they've been exposed to the novel coronavirus are clamoring for antibody tests - blood screens that can detect who has previously been infected and, the hope is, signal who is protected from another case of Covid-19."

"n the nearly 20 years since the publication of this report, numerous stakeholders have sought to reinvent and redesign the US health care system to make it, as the report called for, safe, effective, patient-centered, timely, efficient, and equitable. Researchers have engaged in rigorous and innovative assessments to identify promising approaches. Policy makers, practitioners, and payers have made changes to health policy and clinical practice and instituted various payment reforms and demonstration programs. Yet, despite the tremendous work of the past 20 years, we have not achieved a health care system that is truly patient centered and equitable."

Recommended by Tyler Orion: "PCORI funds studies that can help patients and those who care for them make better-informed healthcare choices."

Tyler - Here are some important FAQs https://help.pcori.org/hc/en-us/categories/200010230-Applicant-Resources I think we might consider a project under their "Accelerating Patient-Centered Outcomes Research & Methodological Research" which is explained here https://www.pcori.org/about-us/our-programs/clinical-effectiveness-and-decision-science

VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials [5,6] of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15 [7]. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age [8]. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017 [9].